No significant activity or favorable toxicity profile was found with sapanisertib when treating patients with refractory metastatic renal cell carcinoma (mRCC) regardless of mTOR or PTEN status, according to data presented during the 2020 Genitourinary Cancers Symposium.
Results from the phase 2 study (NCT03097328) found, at median follow-up of 10.4 months (range, 1.0-27.4), the objective response rate (ORR) was 5.3% (n = 2; 90% CI, 1.0%-15.6%). The median progression-free survival (PFS) was 2.5 months (95% CI, 1.8-3.7), and the median overall survival (OS) was 11.2 months (95% CI, 9.3-not reached).
“Sapanisertib had poor tolerability and minimal activity in patients with treatment refractory metastatic RCC, and there was no clear benefit among patients with mTOR or PTEN alterations,” Bradley McGregor, MD, lead study author, and clinical director of the Lank Center for Genitourinary…
